Humana (NYSE:HUM) Stock Price Expected to Rise, Piper Sandler Analyst Says

Humana (NYSE:HUM) had its price target upped by equities researchers at Piper Sandler from $270.00 to $288.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. Piper Sandler’s target price points to a potential upside of 4.32% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and decreased their price objective for the company from $519.00 to $253.00 in a research note on Monday, October 7th. UBS Group lowered their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Morgan Stanley raised their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada cut their price target on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $302.70.

Humana Trading Down 1.2 %

Shares of HUM stock opened at $276.08 on Wednesday. The stock has a market capitalization of $33.24 billion, a P/E ratio of 24.45, a price-to-earnings-growth ratio of 2.02 and a beta of 0.55. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $455.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a 50 day moving average price of $274.16 and a 200 day moving average price of $308.90.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts predict that Humana will post 16.14 EPS for the current fiscal year.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humana

Several large investors have recently modified their holdings of HUM. Atlas Brown Inc. grew its position in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares during the last quarter. Moors & Cabot Inc. lifted its stake in shares of Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after acquiring an additional 40 shares during the period. OLD National Bancorp IN boosted its holdings in shares of Humana by 1.8% in the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock valued at $828,000 after acquiring an additional 45 shares in the last quarter. Your Advocates Ltd. LLP increased its stake in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. Finally, Brooklyn Investment Group raised its holdings in Humana by 6.7% during the third quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock worth $233,000 after purchasing an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.